

Santen Announces Selection and Launch of its Photo-Crosslinking Research and Development Project for Pathologic Myopia Treatment for the Cyclic Innovation for Clinical Empowerment (CiCLE) Program

March 6, 2019 - Santen Pharmaceutical Co., Ltd. (Chairman and CEO: Akira Kurokawa; Head Office: Osaka; hereinafter, "Santen") announced today its launch of a research and development project for photo-crosslinking for the treatment of pathologic myopia. This R&D project has been selected for the Cyclic Innovation for Clinical Empowerment (CiCLE) program of the Japan Agency for Medical Research and Development (AMED).

There is widespread concern about an increase in the number of patients with pathologic myopia which causes severe visual impairments from now on. This R&D project aims to establish photo-crosslinking as a new treatment for pathologic myopia through collaboration between industry, academia and government, in order to prevent patients from suffering visual impairments. With support from AMED, Santen will promote this R&D project in collaboration with National University Corporation Tokyo Medical and Dental University (located in Yushima, Bunkyo-ku, Tokyo; President: Yasuyuki Yoshizawa), which has accomplished great achievements in clinical research on pathologic myopia, and FiberTech Co., Ltd. (Head Office: Sakura City, Chiba Prefecture) with extensive expertise in development of optical medical devices for ophthalmic treatment.

About CiCLE

Promoting the establishment of infrastructure to respond to medical needs, the creation of an environment for open innovation and venture development based on industry-academia-government collaboration.

About National University Corporation Tokyo Medical and Dental University (TMDU)

Located in Japan's historic district for higher education, TMDU is Japan's only comprehensive medical university and graduate school. The university provides advanced medical treatment through a fusion of the medical and dental fields and works to cultivate and contribute to human health and the well-being of society. TMDU comprises the Faculty of Medicine, the Faculty of Dentistry, the College of Liberal Arts and Sciences; the Graduate School of Medical and Dental Sciences; the Graduate School of Health Care Sciences; the Institute of Biomaterials and Bioengineering; and the

Medical Research Institute. It aims to make wide-ranging contributions to society by training physicians, dentists, nurses, clinical laboratory technicians, dental hygienists, and dental technicians, who combine a desire to heal with a scientific outlook; and working to nurture outstanding medical practitioners and researchers and building research and academic systems in the medical and life science fields.

About FiberTech

FiberTech offer less-invasive and non-invasive endoscopes and other medical devices, thereby provide gentle remedies to patients and medical staffs. We are proud of our products that help saving lives and fighting diseases. Our mission is to contribute to society emphasizing our ultra-thin endoscope know-how and utilizing "Tsunagu" Technologies amongst human lives.
<http://www.fibertech.jp/eng/>

About Santen

As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in over 60 countries. With scientific knowledge and organizational capabilities nurtured over a nearly 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society. For more information, please visit Santen's website (www.santen.com).